News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) Completes $3.6 Billion Takeover of Human Genome Sciences, Inc. (HGSI)


8/6/2012 7:03:36 AM

Washington Business Journal by Jeff Clabaugh, Broadcast/Web Reporter

GlaxoSmithKline PLC has completed its $3.6 billion takeover of Rockville-based Human Genome Sciences Inc., the final step in a months-long struggle for control of the company.

All outstanding shares of Human Genome were acquired for $14.25 per share in cash.

Human Genome Sciences agreed last month to be acquired after earlier rejecting an acquisition offer of $13 per share as too low.

Glaxo has said the acquisition will add to earnings starting in 2013 and will result in $200 million in cost savings by 2015.

The deal fives Glaxo complete ownership of Benlysta, the lupus drug jointly developed by the two companies.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES